Navigation Links
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Date:2/20/2008

ese trials served as the basis for the Company to initiate the large, registration-enabling Phase III trial designed under a special protocol assessment (SPA) with the U.S. Food and Drug Administration (FDA) of VELCADE and rituximab in patients with relapsed follicular lymphoma. The Company is on track to complete patient accrual in this Phase III trial in the first half of 2008, with final data expected in 2010. VELCADE is already approved by the FDA to treat relapsed mantle cell lymphoma (MCL). MCL is an aggressive, rapidly progressive subtype of NHL with median life expectancy for a patient with MCL, following first relapse, of one to two years.

About Non-Hodgkin's Lymphoma

NHL is the most common hematological cancer, the fifth leading cause of cancer death and the second fastest-growing form of cancer in the U.S. The prevalence of NHL in the U.S. is approximately 400,000 patients, including approximately 200,000 patients with diffuse large B-cell lymphoma, 100,000 patients with follicular and marginal zone lymphoma and 10,000 with MCL. There are approximately 54,000 new cases of NHL diagnosed in the U.S. per year, and 19,000 deaths are attributed to the disease annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S. and Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. are co- promoting VELCADE in the U.S. VELCADE is approved in 85 countries worldwide. More than 85,000 patients have been treated with VELCADE globally.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is also indicated for the tre
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
3. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
4. Cellectar Expands Clinical Management Team
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 Research and Markets ... Gloves (Exam and Surgical) Markets Worldwide 2014" report ... The purpose of this report is ... Medical (Exam and Surgical) Gloves. The report discusses key ... products. Topics covered include product definitions, strategies, ...
(Date:7/23/2014)... WASHINGTON , July 23, 2014  Nearly 8,000 ... for Cardinal Health,s annual Retail Business Conference (RBC), ... & Convention Center. This year,s event encourages pharmacists to ... in their communities and for their future. ... pharmacy owners to network with their peers and learn ...
(Date:7/23/2014)... , July 23, 2014  The management team ... ) will hold a conference call on July ... second quarter ended June 30, 2014.  The call ... 2014Time: , 8:30 am EDTDial-in numbers: , Toll ... (412) 317-0790Webcast (live & archive): , www.columbialabs.com ...
Breaking Medicine Technology:Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 2Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 3Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 4Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 2Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 3Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 4Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 5Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 6Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2
(Date:7/23/2014)... York, NY (PRWEB) July 23, 2014 ... 2 billion dollars by the year 2020, according to ... skin are among the top sellers in the U.S. ... The best wrinkle cream under $100 is now reviewed ... meant to help a first-time or experienced shopper to ...
(Date:7/23/2014)... July 23, 2014 The puffiness that ... using non-surgical techniques, according to a new guide published ... serum sold in the U.S. is now available for ... , The complimentary guide that is now published is ... with under eye puffiness. While surgical techniques are available, ...
(Date:7/23/2014)... has developed a simple, cheap and highly accurate ... which attacks immune deficient individuals such as cancer ... lateral-flow device (LFD), created by Professor Chris Thornton, ... diagnose disease caused by the fungus Aspergillus ... a leading cause of death in acute leukaemia ...
(Date:7/23/2014)... Randy Dotinga HealthDay Reporter ... A powerful drug combo may not be as effective ... on human cells suggests that one of the medications ... this study,s findings aren,t definitive, and there,s still hope ... and lumacaftor, according to the study,s senior author. ...
(Date:7/23/2014)... AB (PRWEB) July 23, 2014 ... of in-home care for seniors, is proud to announce ... Series featuring experts in a wide range of health ... clinical social worker and award-winning author Nancy Kriseman, and ... and ways to prevent burnout by becoming more self-aware. ...
Breaking Medicine News(10 mins):Health News:Best Wrinkle Cream Under $100 Reviewed at Top News Website Online 2Health News:Puffy Eyes Serum Explored in Complimentary Guide Released at Consumer News Website 2Health News:New device detects deadly lung disease 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 3Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3
... it,s no better than standard treatment, one expert says, ... the indigestion and heartburn that bother many women as ... Indigestion is common during pregnancy, with up to 80 ... reflux, belching and bloating. Symptoms tend to worsen over ...
... - Europe Cosmetiques and Probiox announced today that both ... respect to oxidative stress profiling. Under this agreement, Europe ... and Mexico. , According to Manon Pilon, Founder President ... the leader in the Medical SPA industry, and is ...
... PEMBROKE, Bermuda, June 9 Allied World ... Assurance Company,Holdings, Ltd (NYSE: AWH ), today ... product offered in the United States. The,complimentary service, called ... crisis management resources in the,event of a catastrophe. , ...
... Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today ... trial of sodium oxybate (JZP-6) for the treatment of ... Professional Sleep Societies (APSS) 2009 Annual Meeting in Seattle, ... (EULAR) Congress in Copenhagen, Denmark. , , Following ...
... Programs Designed to Address High Risks for New Dialysis Patients ... , DENVER, June 9 DaVita Inc. (NYSE: ... those diagnosed with chronic kidney disease (CKD), today commended Kidney ... Kidney Care (PEAK) campaign. Kidney Care Partners - a ...
... New techniques bring equivalent results without the potential dangers, ... Researchers say they,ve developed new techniques for reducing ... disease. , The use of these radiation-lowering strategies did ... computed tomography angiography (CCTA), an increasingly popular weapon in ...
Cached Medicine News:Health News: Acupuncture May Relieve Heartburn In Pregnancy 2Health News: Acupuncture May Relieve Heartburn In Pregnancy 3Health News:"Alliance between Europe Cosmetiques and Probiox brings new oxydative stress profiling technologies to North America" 2Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 2Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 3Health News:Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 2Health News:Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 3Health News:Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 4Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 2Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 3Health News:Reduced-Radiation Heart Scans Don't Compromise on Quality 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: